1st Counsel – Lifestyle
Author:
HUTCHMED (China) Limited
HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026
April 8, 2026
HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China
March 22, 2026
HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China
March 9, 2026
Intended Retirement of Independent Non-executive Director and changes of composition of board committees
March 6, 2026
HUTCHMED Reports 2025 Full Year Results and Business Updates
March 5, 2026